Key Points
- AbbVie EVP Perry Siatis sold 22,381 shares at an average price of $230 on Feb. 25, a transaction worth $5,147,630 that reduced his holding by 36.98% to 38,137 shares.
- AbbVie beat quarterly estimates with $2.71 EPS and $16.62 billion revenue, and set FY2026 guidance of 14.370–14.570 EPS (Q1 guidance 2.970–3.010), while the company pays a quarterly dividend of $1.73 ($6.92 annual, ~3.0% yield).
- Recent positive catalysts include federal support in AbbVie’s Colorado 340B legal challenge and FDA approval of a first‑in‑class oral CLL regimen plus a $380M U.S. manufacturing buildout, events that could help near‑ to medium‑term revenue and margin prospects.
AbbVie Inc. (NYSE:ABBV - Get Free Report) EVP Perry Siatis sold 22,381 shares of the company's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
AbbVie Price Performance
Shares of ABBV opened at $231.69 on Friday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a market cap of $409.66 billion, a PE ratio of 98.17, a P/E/G ratio of 0.78 and a beta of 0.35. The stock has a 50-day moving average of $224.34 and a 200-day moving average of $222.94.
AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to analysts' expectations of $16.39 billion. During the same quarter last year, the firm posted $2.16 earnings per share. The company's revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.
AbbVie Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is 293.22%.
Institutional Investors Weigh In On AbbVie
A number of hedge funds have recently modified their holdings of ABBV. Vanguard Group Inc. raised its stake in AbbVie by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock valued at $41,306,353,000 after purchasing an additional 3,032,438 shares in the last quarter. State Street Corp lifted its holdings in shares of AbbVie by 1.4% during the 4th quarter. State Street Corp now owns 80,940,931 shares of the company's stock worth $18,494,193,000 after acquiring an additional 1,119,274 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after acquiring an additional 4,190,487 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company's stock worth $4,970,848,000 after acquiring an additional 1,517,222 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company's stock valued at $5,900,617,000 after acquiring an additional 356,394 shares during the last quarter. Institutional investors own 70.23% of the company's stock.
AbbVie News Roundup
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: RBC Capital Markets initiated coverage with an Outperform rating and a $260 price target, arguing AbbVie’s growth is durable and the shares have been punished by short‑term competitive concerns — a bullish analyst catalyst that likely supported buying interest. RBC Launches AbbVie Coverage
- Positive Sentiment: The U.S. Justice Department publicly backed AbbVie’s challenge to Colorado’s 340B guidance, giving the company federal support in a case that could affect how discounts are applied and future margin outcomes in that program. DOJ backs AbbVie in 340B fight
- Positive Sentiment: Federal agencies also supported AbbVie’s position in Colorado in separate coverage, reinforcing regulatory/legal momentum in the company’s favor that could protect 340B economics if courts rule similarly. Feds back AbbVie in Colorado 340B fight
- Positive Sentiment: AbbVie received FDA approval for a first‑in‑class, all‑oral fixed‑duration regimen for untreated CLL and announced a $380M U.S. manufacturing buildout to support neuroscience and obesity programs — both add to medium‑term revenue and capacity upside. AbbVie’s CLL Breakthrough And US$380m Build Out
- Positive Sentiment: AbbVie reported fresh real‑world/post‑marketing data updates for upadacitinib (Rinvoq) in teens with eczema — data investors should watch for uptake and label/market expansion implications for a key growth franchise. Upadacitinib Study in Teens
- Neutral Sentiment: Zacks highlights AbbVie as a top long‑term value stock based on style scores — a framing piece that supports a buy thesis but doesn’t present new company‑specific catalysts. Why AbbVie is a Top Value Stock
- Neutral Sentiment: Dividend and longer‑term outlook pieces (Seeking Alpha / Motley Fool) reiterate AbbVie’s income profile and buy‑and‑hold case, helpful context for income investors but unlikely to trigger near‑term moves alone. Health Care Q4 Dividend Roundup
- Negative Sentiment: A Tennessee court rejected AbbVie’s challenge to that state’s contract‑pharmacy law, a loss that keeps legal/regulatory uncertainty around 340B implementation and potential margin headwinds in some states. AbbVie Loses Challenge in Tennessee
Wall Street Analysts Forecast Growth
ABBV has been the subject of several analyst reports. Piper Sandler increased their price objective on AbbVie from $289.00 to $299.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 18th. Morgan Stanley raised their price objective on AbbVie from $269.00 to $270.00 and gave the company an "overweight" rating in a research note on Thursday, February 5th. Scotiabank assumed coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a "sector outperform" rating and a $280.00 target price for the company. BMO Capital Markets reiterated an "outperform" rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday, January 15th. Finally, Evercore dropped their price target on shares of AbbVie from $232.00 to $228.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of "Moderate Buy" and an average price target of $253.15.
Get Our Latest Report on ABBV
AbbVie Company Profile
(
Get Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
